[go: up one dir, main page]

WO2023062354A3 - Nanoparticulate formulation - Google Patents

Nanoparticulate formulation Download PDF

Info

Publication number
WO2023062354A3
WO2023062354A3 PCT/GB2022/052570 GB2022052570W WO2023062354A3 WO 2023062354 A3 WO2023062354 A3 WO 2023062354A3 GB 2022052570 W GB2022052570 W GB 2022052570W WO 2023062354 A3 WO2023062354 A3 WO 2023062354A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
nanoparticulate formulation
medical treatment
nanoparticulate compositions
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2022/052570
Other languages
French (fr)
Other versions
WO2023062354A2 (en
Inventor
Brian Horsburgh
Mark David Moody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newimmune Ii LLC
Original Assignee
Newimmune Ii LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newimmune Ii LLC filed Critical Newimmune Ii LLC
Priority to US18/700,066 priority Critical patent/US20240335383A1/en
Priority to EP22790012.3A priority patent/EP4415684A2/en
Publication of WO2023062354A2 publication Critical patent/WO2023062354A2/en
Publication of WO2023062354A3 publication Critical patent/WO2023062354A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.
PCT/GB2022/052570 2021-10-11 2022-10-11 Nanoparticulate formulation Ceased WO2023062354A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US18/700,066 US20240335383A1 (en) 2021-10-11 2022-10-11 Nanoparticulate formulation
EP22790012.3A EP4415684A2 (en) 2021-10-11 2022-10-11 Nanoparticulate formulation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163254253P 2021-10-11 2021-10-11
US63/254,253 2021-10-11
GB2201351.0 2022-02-02
GBGB2201351.0A GB202201351D0 (en) 2022-02-02 2022-02-02 Nanoparticulate formulation
US202263321886P 2022-03-21 2022-03-21
US63/321,886 2022-03-21

Publications (2)

Publication Number Publication Date
WO2023062354A2 WO2023062354A2 (en) 2023-04-20
WO2023062354A3 true WO2023062354A3 (en) 2023-06-01

Family

ID=80621217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/052570 Ceased WO2023062354A2 (en) 2021-10-11 2022-10-11 Nanoparticulate formulation

Country Status (3)

Country Link
CA (1) CA3179062A1 (en)
GB (1) GB202201351D0 (en)
WO (1) WO2023062354A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118141942B (en) * 2024-01-29 2024-10-01 中国农业大学 Carrier for improving curcumin colon utilization rate and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899897A (en) * 1994-08-05 1996-04-16 Shionogi & Co Ltd Interleukin-2 adsorption type lipid globule
WO2013155487A1 (en) * 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
US20160331743A1 (en) * 2014-01-10 2016-11-17 Urogen Pharma Ltd Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
US20180296850A1 (en) * 2017-04-14 2018-10-18 Tianxin Wang Reagents and methods for cancer treatment using Magnetic particle
WO2020220000A1 (en) * 2019-04-25 2020-10-29 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899897A (en) * 1994-08-05 1996-04-16 Shionogi & Co Ltd Interleukin-2 adsorption type lipid globule
WO2013155487A1 (en) * 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
US20160331743A1 (en) * 2014-01-10 2016-11-17 Urogen Pharma Ltd Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
US20180296850A1 (en) * 2017-04-14 2018-10-18 Tianxin Wang Reagents and methods for cancer treatment using Magnetic particle
WO2020220000A1 (en) * 2019-04-25 2020-10-29 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OU WENQUAN ET AL: "Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors", APPLIED MATERIALS & INTERFACES, vol. 11, no. 40, 9 October 2019 (2019-10-09), US, pages 36333 - 36346, XP055963893, ISSN: 1944-8244, DOI: 10.1021/acsami.9b11371 *

Also Published As

Publication number Publication date
GB202201351D0 (en) 2022-03-16
WO2023062354A2 (en) 2023-04-20
CA3179062A1 (en) 2023-04-11

Similar Documents

Publication Publication Date Title
AU2014264224B2 (en) Doped metal oxide nanoparticles of and uses thereof
EP4442241A3 (en) Retinol replacement in skin treatment
WO2020083971A3 (en) New anthelmintic compounds
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
NZ722927A (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2022013596A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GB0814302D0 (en) Compounds and methods
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
EP4342473A3 (en) Compounds useful in hiv therapy
WO2016142708A3 (en) Pharmaceutical composition
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MX2012001529A (en) 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators.
WO2023062354A3 (en) Nanoparticulate formulation
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MX2020007062A (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof.
SI2628754T1 (en) A process for the production and use of copolymer of sodium carbosimethyl cellulose and gossypol
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
CN103735570A (en) Oral care solution for preventing oral fungal infection
WO2012123924A3 (en) Antimicrobial composition including at least one or more aggregation(s) silver particles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22790012

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2022790012

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022790012

Country of ref document: EP

Effective date: 20240513